JOHN HOPE FRANKLIN CENTER

A trial suggests 'watch and wait' approach may be safe for low-risk DCIS breast cancer, potentially avoiding invasive treatments. Experts propose redefining DCIS as not cancer. Other breakthroughs include new drugs and weight-loss jabs for cancer prevention and treatment.

The FDA approved remestemcel-L (Ryoncil), the first mesenchymal stromal cell therapy for pediatric patients with steroid-refractory acute graft-versus-host disease. The approval is based on a phase III trial showing 30% complete response and 41% partial response at day 28. Remestemcel-L, derived from MSCs, aims to reduce systemic inflammation.

Utility work at Amazon's HQ2 Phase 2 site concluded, but construction timeline remains unclear. Amazon has until April 2025 to finalize plans or seek an extension. The company paused PenPlace construction in March 2023, with expectations of a one-year delay. Amazon's return to in-person work five days a week starting next month may influence future office space needs.

A study in JAMA Network Open reveals that negatively biased language in patient handoffs reduces empathy and accuracy in recalling health details, potentially influencing care. Standardized handoffs and patient advocacy can mitigate these effects.

University of Arizona's research activity exceeded $1 billion in FY24, focusing on global challenges like energy, health, and national security. The university ranks among top research institutions and maintains its No. 1 ranking in astronomy and astrophysics. Research advances human knowledge, prepares students, and strengthens communities.

Two studies found that using SSPedi, a tool for young cancer patients to report symptoms, led to fewer symptoms and better supportive care. The trials, published in JAMA and JAMA Pediatrics, showed that daily symptom reporting reduced distress and improved symptom management. The findings suggest that patient-reported outcomes can significantly improve care for young cancer patients.

ASH meeting featured studies on BTK inhibitors in CLL, including Jaypirca's Phase 3 trial showing improved progression-free survival and fewer side effects. AstraZeneca's Calquence combined with Venclexta reduced progression risk by 35%. Pfizer's Oxbryta withdrawal due to safety concerns raised questions on sickle cell drug approvals. Bristol Myers Squibb presented positive survival data for its GPRC5D-targeted CAR-T therapy, arlo-cel, in multiple myeloma.

Johnson & Johnson seeks approval for Darzalex to treat high-risk smoldering myeloma, with AQUILA trial showing reduced risk of disease progression. GSK's Blenrep, after withdrawal, shows improved survival in DREAMM-7 trial. Emerging efforts aim to ease conditioning for genetic treatments in sickle cell disease. Kura Oncology's menin inhibitor shows promising results in AML, facing competition from J&J and Syndax. Pfizer's Oxbryta withdrawal for sickle cell disease remains unexplained.

Theralase®'s Phase 2 study for BCG-Unresponsive NMIBC CIS shows 68.3% Total Response (CR and IR) and 100% safety. 14 clinical sites in North America are enrolling patients, with an additional site planned for 1Q2025.

The Hastings Center announces its 2024 fellows, leaders in bioethics addressing global issues like infectious disease, AI in health, neuroscience, reproductive rights, genetics, and disability.